REHOVOT, Israel, June 14, 2011 /PRNewswire/ --
D-Pharm Ltd., (TASE: DPRM) announced today publication, on-line, in the International Journal of Stroke the protocol for its ongoing, Phase III, Membrane Activated Chelator Stroke Intervention (MACSI) study. In this study, DP-b99 is being tested for safety and for the ability to improve outcome in moderately severe acute ischemic stroke patients. The article is available on-line at the following link http://onlinelibrary.wiley.com/doi/10.1111/j.1747-4949.2011.00608.x/abstract and will appear in the journal'’s August, 2011 print edition.
Dr. Gilad Rosenberg, D-Pharm'’s V.P. of Clinical Development commented; "DP-b99 is the most advanced industry-developed neuroprotective agent in clinical development. Benefitting from the MACSI Steering Committee'’s many years of experience in clinical stroke research, we have gone to a great effort to include an innovative trial design that incorporates many of the lessons learned from past studies."
The MACSI study is one on the largest randomized, double blind, placebo-controlled Phase III stroke studies currently ongoing. Its primary objective is to evaluate the safety and therapeutic effects of intravenous 1.0mg/kg/day DP-b99, initiated within nine-hours of stroke onset in patients with moderately severe hemispheric acute ischemic stroke. The primary efficacy outcome is the mRS score at day 90 which will be compared between treatment groups using a ‘shift', or distribution, analysis.
The MACSI study is enrolling 770 patients, with recruitment in over 100 clinical sites in North America, Europe, South America, South Africa and Israel. The protocol, now published, was agreed with the U.S. FDA under the Special Protocol Assessment (SPA) procedure and the DP-b99 development program has been granted Fast Track status by the U.S. FDA.
According to the MACSI protocol, a Data Safety Monitoring Board (DSMB), should periodically review safety data from patients enrolled into the study. The DSMB, which includes independent experts in stroke, neurology and biostatistics, recently recommended to the MACSI Steering Committee that the study continue in its present design without changes to the protocol.
DP-b99 is a unique broad-spectrum neuroprotective drug that addresses an array of brain damaging processes occurring in stroke patients. Both preclinical and clinical Phase I and II studies indicate a favorable efficacy and safety profile for DP-b99. In the Phase IIb trial in 150 ischemic stroke patients, DP-b99 increased by two-fold the percentage of patients that recovered from ischemic stroke. DP-b99 may be administered within a nine hour therapeutic window.
Every year around 1.5 million people in the U.S., Western Europe and Japan suffer an acute stroke. Stroke is a leading cause of death in the western world and around 50% of stroke survivors suffer from some form of severe disability. According to the American Heart Association (AHA) the annual economic burden of stroke in the U.S. was around $70B in 2009. Currently, between 2-5% of stroke patients receive tissue plasminogen activator (tPA), the only drug currently approved for treatment of acute stroke in the U.S.
D-Pharm (http://www.dpharm.com) is a clinical stage, biopharmaceutical company pioneering the development of lipid-like therapeutics, and has generated a rich pipeline of patent protected proprietary products. D-Pharm'’s pipeline includes advanced clinical stage products, DP-b99 for treatment of ischemic stroke patients and DP-VPA, a novel drug for treatment of epilepsy, bipolar disorder and prophylaxis of migraine. DP-VPA, a prodrug of valproic acid, is in Phase II clinical development. DP-460 is in preclinical development intended as an oral, disease-modifying therapy for Alzheimer's disease. Other mimics of bioactive lipids, LipidoMimetix, are at an earlier developmental stage for cancer.
D-Pharm was established in 1993 at the initiative of Dr. Alex Kozak, President and CEO. In August 2009 the Company completed the first offering of its shares on the Tel Aviv stock exchange. The largest shareholder in the company is Clal Biotechnology Industries (46%).
Statements in this press release that are not historical facts are forward-looking information, as defined in the Securities Law, based on information available to D-Pharm at the time of this press release. The estimations could, some or all, be unrealized, or could be realized in significantly different ways than expected.
For further information please contact:
SOURCE D-Pharm Ltd